VJOncology is committed to improving our service to you

ASCO 2017 | Results of the combined inhibition of IDO1 and PD-L1 in locally advanced or metastatic solid tumors

VJOncology is committed to improving our service to you

Howard Burris

Howard A. Burris, MD, FASCO from the Sarah Cannon Research Institute, Nashville, TN, summarizes the Phase I trial of the combination of inhibitors of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients with advanced or metastatic solid tumors. Dr Burris explains that blocking IDO1 leads to a more favorable environment for immunotherapy. This response was seen in various tumor types, such as melanoma, pancreatic, ovarian and prostate cancer, with durable and long-lasting benefits. Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter